NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

dstock07734,

I agree. We can see things changing and shifting on the BP landscape. “Now we are in the era of immunotherapy.” —Dr. Pazdur, FDA

Dr. Butterfield is an interesting recent addition to the Merck team, especially since she has studied the role of dendritic cells in cancer treatment…

“Dr. Lisa Butterfield is a distinguished expert in cancer immunotherapy, particularly in the development of cancer vaccines and cellular therapies. Her research focuses on utilizing dendritic cells and T-cell responses to create personalized immunotherapies targeting cancers like melanoma, hepatocellular carcinoma, and other solid tumors. She has also explored biomarkers and the immune system’s role in responding to checkpoint inhibitors, such as PD-1 and CTLA-4 inhibitors.

At Merck, Dr. Butterfield holds the position of Distinguished Scientist, where she contributes her expertise in immunotherapy, helping advance Merck's work in cancer treatments, particularly those involving immune checkpoint inhibitors like Keytruda (pembrolizumab). In addition to her role at Merck, she has held leadership positions at various research institutions and organizations, including the Parker Institute for Cancer Immunotherapy.”
https://pubmed.ncbi.nlm.nih.gov/?term=Butterfield%20LH%5BAuthor%5D

This YouTube interview from a few years ago in 2021 was before she was hired by Merck in 2023, and her comments are quite interesting in retrospect.

Starting at timestamp 17:00, they begin discussing Provenge, GVAX, dendritic cells, T cells, tumor microenvironment, etc.

Timestamp 25:15


Timestamp 32:55


I really liked this question during the YouTube interview at timestamp 43:00 …





—Chen & Mellman